Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Menopausal hormone therapy (HT) prescribing practices have evolved over the last few decades guided by the changing understanding of the treatment’s risks and benefits. Since the Women’s Health Initiative (WHI) trial results in 2002, including post-intervention analysis and cumulative 18-year follow up, it has become clear that the risks of HT are low for healthy women less than age 60 or within ten years from menopause. For those who are experiencing bothersome vasomotor symptoms, the benefits are likely to outweigh the risks in view of HT’s efficacy for symptom management. HT also has a role in preventing osteoporosis in appropriate candidates for treatment. A comprehensive overview of the types, routes, and formulations of currently available HT, as well as HT’s benefits and risks by outcomes of interest are provided to facilitate clinical decision making.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889 · cited 3×
“The WHI trial showed that unopposed oCEE has less adverse cardiovascular outcomes than an estrogen plus progestin formulation (33, 38, 50).”
BackgroundPrevalence and Trends in Obesity Among US Adults, 1999-2008
Flegal, K. M. (2010) · JAMA · doi:10.1001/jama.2009.2014 · Cited by 7,580
Estrogen plus Progestin and the Risk of Coronary Heart Disease
Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030808 · Cited by 2,065 · cited 1×
“In contrast, those randomized to oCEE + MPA at least 20 years after menopause had significantly higher risk of CHD compared to placebo (6, 7).”
Self-citationManson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., Anderson, G., Howard, B. V., Thomson, C. A., LaCroix, A. Z., et al. (2013) · JAMA · doi:10.1001/jama.2013.278040 · Cited by 1,650 · cited 8×
“Furthermore, there was no significant difference in CVD mortality when groups were stratified by age (7, 46).”
BackgroundInfluentialSelf-citationGrodstein, F., Manson, J. E., Colditz, G. A., Willett, W. C., Speizer, F. E., & Stampfer, M. J. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-12-200012190-00008 · Cited by 1,063
Self-citationTreatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
Vascular effects of early versus late postmenopausal treatment with estradiol
Hodis, H. N., Mack, W. J., Henderson, V. W., Shoupe, D., Budoff, M. J., Hwang-Levine, J., Li, Y., Feng, M., Dustin, L., Kono, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505241 · Cited by 779 · cited 8×
“Similarly, ELITE found that oral estradiol did not impact verbal memory, executive functions, or global cognition in women who started HT 6 years within menopause or 10 years or more after menopause (77).”
BackgroundInfluentialSalpeter, S. R., Walsh, J. M. E., Ormiston, T. M., Greyber, E., Buckley, N. S., & Salpeter, E. E. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00545.x · Cited by 640 · cited 8×
“OCEE contributes to better lipid profiles when compared to oral esterified estrogens (62).”
BackgroundMethodInfluentialHormone therapy for preventing cardiovascular disease in post-menopausal women
Boardman, H. M., Hartley, L., Eisinga, A., Main, C., Roqué i Figuls, M., Bonfill Cosp, X., Gabriel Sanchez, R., & Knight, B. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002229.pub4 · Cited by 612 · cited 5×
“All-Cause Mortality (13, 36) E Trend toward decreased risk”
BackgroundMethodInfluential
Cited by
Unraveling female reproductive senescence to enhance healthy longevity
Dong, L., Teh, D. B. L., Kennedy, B. K., & Huang, Z. (2023) · Cell Research · doi:10.1038/s41422-022-00718-7 · Cited by 101
“Postmenopausal women are at higher risk of developing osteoporosis, and they form the largest number of osteoporotic cases.(80,81) Serum estrogen levels are directly related to bone mineral density and inversely linked to bone fracture risks.”
BackgroundThe power of phages: revolutionizing cancer treatment
Islam, M. S., Fan, J., & Pan, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1290296 · Cited by 50
Metadata
- Authors
- Mehta, J., Kling, J. M., & Manson, J. E.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2021-03-26
- Volume
- 12
- Pages
- 564781-564781
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W3147034087
- Cited by
- 186
- References
- 13
- FWCI
- 17.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts. https://app.cochat.ai/papers/10.3389/fendo.2021.564781
- The paper
- Mehta, J., Kling, J. M., & Manson, J. E. (2021). Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2021.564781
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.